Associated Papers
rs2231142 (421 C>A, Q141K) Is More Functionally Influential than rs2231137 (34 G>A, V12M) on Anticancer Drug Resistance Mediated by the ABCG2 Haplotype In Vitro.
Yamashita M et al.
International Journal of Molecular Sciences, 2025
Population-specific putative causal variants shape quantitative traits.
Koyama S et al.
Nature Genetics, 2024
Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinol.
Kasten A et al.
Expert Opinion on Drug Metabolism & Toxicology, 2024
A Pan-Cancer Landscape of ABCG2 across Human Cancers: Friend or Foe?
Lyu C et al.
International Journal of Molecular Sciences, 2022
RBCeq: A robust and scalable algorithm for accurate genetic blood typing.
Jadhao S et al.
Ebiomedicine, 2022
Multidrug efflux transporter ABCG2: expression and regulation.
Kukal S et al.
Cellular and Molecular Life Sciences : Cmls, 2021
The Role of ABCG2 in the Pathogenesis of Primary Hyperuricemia and Gout-An Update.
Eckenstaler R et al.
International Journal of Molecular Sciences, 2021
Medically Important Alterations in Transport Function and Trafficking of ABCG2.
Homolya L
International Journal of Molecular Sciences, 2021
The ABCG2/BCRP transporter and its variants - from structure to pathology.
Sarkadi B et al.
Febs Letters, 2020
Genetic Diversity in Drug Transporters: Impact in African Populations.
Rajman I et al.
Clinical and Translational Science, 2020
ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors.
Safar Z et al.
Expert Opinion on Drug Metabolism & Toxicology, 2019
ATP-Binding Cassette Transporters in the Clinical Implementation of Pharmacogenetics.
López-Fernández LA
Journal of Personalized Medicine, 2018
Polymorphisms of the Multidrug Pump ABCG2: A Systematic Review of Their Effect on Protein Expression, Function, and Drug Pharmacokinetics.
Heyes N et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2018
An update on the genetics of hyperuricaemia and gout.
Major TJ et al.
Nature Reviews. Rheumatology, 2018
Pharmacogenetic Aspects of the Interaction of AT1 Receptor Antagonists With ATP-Binding Cassette Transporter ABCG2.
Ripperger A et al.
Frontiers in Pharmacology, 2018
Transmembrane Domain Single-Nucleotide Polymorphisms Impair Expression and Transport Activity of ABC Transporter ABCG2.
Sjöstedt N et al.
Pharmaceutical Research, 2017
Multiple common and rare variants of ABCG2 cause gout.
Higashino T et al.
Rmd Open, 2017
Impact of genetic variability in the ABCG2 gene on ABCG2 expression, function, and interaction with AT1 receptor antagonist telmisartan.
Deppe S et al.
Biochemical and Biophysical Research Communications, 2014
Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.
Noguchi K et al.
Pharmacogenomics and Personalized Medicine, 2014
Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.
Schnepf R et al.
Expert Opinion on Drug Metabolism & Toxicology, 2013
Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
Nakanishi T et al.
Chinese Journal of Cancer, 2012
Ubiquitin-mediated proteasomal degradation of ABC transporters: a new aspect of genetic polymorphisms and clinical impacts.
Nakagawa H et al.
Journal of Pharmaceutical Sciences, 2011
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Sai K et al.
Cancer Chemotherapy and Pharmacology, 2010
Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis.
Ishikawa T et al.
Advances in Pharmacological Sciences, 2010
Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.
Furukawa T et al.
Pharmaceutical Research, 2009
Quality control of human ABCG2 protein in the endoplasmic reticulum: ubiquitination and proteasomal degradation.
Wakabayashi-Nakao K et al.
Advanced Drug Delivery Reviews, 2009
Human ABC transporters ABCG2 (BCRP) and ABCG4.
Koshiba S et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2008
Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2.
Nakagawa H et al.
The Biochemical Journal, 2008
In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs.
Tamura A et al.
Drug Metabolism and Pharmacokinetics, 2007
Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2.
Tamura A et al.
Cancer Science, 2007
[Genetic polymorphisms of human ABC transporter ABCG2: Porphyria risk and ER quality control].
Wakabayashi K et al.
Seikagaku. the Journal of Japanese Biochemical Society, 2007
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs.
Cascorbi I
Pharmacology & Therapeutics, 2006
Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.
Tamura A et al.
Molecular Pharmacology, 2006
The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology.
Cervenak J et al.
Cancer Letters, 2006
Genetic polymorphisms of human ABC transporter ABCG2: development of the standard method for functional validation of SNPs by using the Flp recombinase system.
Tamura A et al.
Journal of Experimental Therapeutics & Oncology, 2006
Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta.
Kobayashi D et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005
Functional analysis of SNPs variants of BCRP/ABCG2.
Kondo C et al.
Pharmaceutical Research, 2004
Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan.
Itoda M et al.
Drug Metabolism and Pharmacokinetics, 2003